Chemical Structure (Xeloda 01)
Xeloda
Product Images NDC 61269-470
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Xeloda (NDC 61269-470). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by H2-pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Xeloda 02)
This is data from a clinical trial comparing the efficacy of two chemotherapeutic drugs, 5-FU+ LEUCOVORIN and CAPECITABINE. The data shows the number of patients in each treatment group at different time points, expressed in months since randomization. The percentage of patients still at risk (i.e. alive or disease-free) at each time point is also provided.*
Figure 2 (Xeloda 03)
This appears to be a graph showing survival rates for two different treatment groups over a period of 96 months since randomization. The two treatments are 5-FU+ LEUCOVORIN and CAPECITABINE and their respective survival rates are shown in the graph.*
Figure 3 (Xeloda 04)
This is a chart with estimated probability percentages for two different chemotherapy treatments over a certain period of time. The treatments mentioned are 5-FU + Leucovorin (Mayo Regimen) and Xeloda 1250 taken twice daily intermittently. The chart shows the estimated probability of success rates for each treatment over time. The horizontal axis represents the number of days, and the vertical axis represents the percentage of success rate.*
Figure 4 (Xeloda 05)
This appears to be a chart showing the estimated probability for a treatment involving "Docetaxel" administered at varying doses and frequencies over a period of three weeks. The chart displays a probability scale ranging from 0 to 1 and shows the estimated probability for the treatment at each dose and frequency combination over a 800 day period. The text does not provide any further context or information.*
Figure 5 (Xeloda 06)
Principal Display Panel (150 mg Tablet Bottle Carton)
This is a description of Xeloda, a medication with NDC 61269-470-60. It is in tablet form, with each containing 150 mg of capecitabine. There are 60 tablets in each package provided by CHEPLAPHARM. The text also includes a warning that Xeloda is a hazardous drug.*
Principal Display Panel (500 mg Tablet Bottle Carton)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
